semaglutide for heart patients GLP-1 agonists like Ozempic may reduce cardiovascular events by 20% FDA Approves First Treatment to

As part of our routine safety review process for tirzepatide, we have ongoing discussions with regulators regarding potential safety topics, and we will continue to review data, including any data regarding ophthalmic issues, the company said in a statement to TODAY.com

Whether this translates to human risk is not established, but the medication is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

M.HellerD

If you havent registered for the 84 th Scientific Sessions, register today to access the valuable meeting content through Aug